Editorial Standards

Latest News Today maintains rigorous editorial standards. Our team verifies information from trusted sources and provides context to help readers understand complex stories.

Last Updated: Thursday, October 1, 2026 at 04:03 PM
Category: Id

Editor's Note

Latest News Today provides comprehensive coverage and analysis of breaking news stories. This article is part of our ongoing coverage of wbna42337361, bringing you verified information from trusted sources with added context and expert perspective.

Why This Matters: Understanding the full context of this story helps readers make informed decisions and stay updated on developments that impact our community.

Pain Therapeutics to Present at Needham Health Care Conference

SAN MATEO, Calif., March 30, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that Peter S. Roddy, Vice President and Chief Financial Officer, will present at the 10th Annual Needham Health Care Conference in New York City on Wednesday, April 6th at 4:00 p.m. Eastern Time.  

SAN MATEO, Calif., March 30, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that Peter S. Roddy, Vice President and Chief Financial Officer, will present at the 10th Annual Needham Health Care Conference in New York City on Wednesday, April 6th at 4:00 p.m. Eastern Time.  

A live audio webcast of the presentation will be available on the company's website homepage at . A replay of the audio webcast will continue to be available on the website for one month.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. We conceived, developed, trademarked and partnered REMOXY®, a unique abuse-resistant formulation of oxycodone. A New Drug Application for REMOXY is on file with the FDA, with a PDUFA date of June 23, 2011. Pfizer, Inc. is our commercial partner for REMOXY and three other pain medications (abuse-resistant formulations of hydromorphone, hydrocodone and oxymorphone). In addition, we are developing a novel radio-labeled monoclonal antibody to treat metastatic melanoma, a deadly form of skin cancer. We are also working on a new treatment for patients with hemophilia, a genetic disorder in which patients are unable to stop bleeding. For more information, please visit .

CONTACT: Judy Ishida Administrative Manager Pain Therapeutics, Inc. IR@paintrials.com 650-645-1924